Original paper

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer

Volume: 4, Issue: 2, Pages: 305 - 309
Published: Apr 1, 2021
Abstract
In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with androgen deprivation therapy (ADT). A subgroup of these patients show oligoprogression, with the progression of only a limited number of metastatic spots, while all other metastases remain controlled...
Paper Details
Title
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer
Published Date
Apr 1, 2021
Volume
4
Issue
2
Pages
305 - 309
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.